DRUG
1-month GnRH
1-month GnRH (goserelin 3.6 mg depot or goserelin 3.6 mg implant or leuprolide 3.75 mg depot) +endocrine therapy (aromatase inhibitor/tamoxifen±CDK4/6 inhibition)
Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.
Status
Not yet recruiting
Phase
Phase 2
Enrollment
100
Locations
0
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This is a multicenter, prospective, randomized controlled, phase II study. The primary objective is to evaluate the effect of endocrine therapy modification (switching from a 3-month to a 1-month GnRHa) versus continuation of the 3-month GnRHa on E2 control at 3 months in young patients with hormone receptor-positive breast cancer and iOFS.
Full detailed description
In China, breast cancer occurs at a young age, with a peak incidence at 40-49 years; patients aged ≤45 years account for 20%-24% of cases, and this proportion is increasing. Ovarian function suppression (OFS) combined with aromatase inhibitor (AI) or tamoxifen (TAM), with or without CDK4/6 inhibitors, has become a preferred adjuvant endocrine therapy for intermediate to high-risk premenopausal hormone receptor-positive (HR+) patients with HR+ breast cancer. AI is effective in premenopausal women only when ovarian estrogen production is suppressed, which can be achieved with GnRH agonists (GnRHa). The 3-month GnRHa formulation is commonly preferred in the real world due to its convenience and reduced injection frequency; however, its effectiveness compared with the 1-month formulation remains a concern. Among premenopausal patients receiving GnRHa combined with AI or TAM, approximately 8% experience incomplete ovarian function suppression (iOFS, E2 ≥30 pg/mL). Persistent iOFS may reduce the efficacy of endocrine therapy and potentially increase the risk of disease recurrence. Current clinical guidelines recommend monitoring serum estradiol (E2) levels during GnRHa treatment and suggest potential management strategies, including switching GnRHa formulations from 3-month to 1-month or modifying endocrine therapy (e.g., AI to TAM). However, evidence supporting these strategies is largely derived from retrospective studies or small case series, and prospective data remain limited. This multicenter, prospective, randomized, phase II study is designed to evaluate whether switching from a 3-month to a 1-month GnRHa can reduce E2 levels to \<30 pg/mL within 3 months in premenopausal HR+ young breast cancer patients with iOFS. This study will also assess the long-term efficacy and safety of this strategy.
Interventions
Treatment arms and agents.
DRUG
3-month GnRH
3-month GnRH (goserelin 10.8 mg implant or leuprolide 11.25 mg depot) + endocrine therapy (aromatase inhibitor/tamoxifen±CDK4/6 inhibition)
Timeline
From registration to results.
First posted
May 28, 2026
Study start
Jun 1, 2026
Primary completion
Sep 1, 2027
Study completion
Jun 1, 2030
Results posted
Not reported
Registry updated
May 28, 2026
Outcomes
What the study measures.
Primary outcomes
Proportion of Participants with E2 <30 pg/mL at 3 Months
Time frame · 3 months post randomization
The primary endpoint is defined as the proportion of patients with E2 \<30 pg/mL at 3 months, comparing patients who switch to GnRHa 1M versus those who continue GnRHa 3M therapy.
Secondary outcomes
Proportion of patients with E2 <30 pg/mL at 6 months after randomization
Time frame · 6 months post randomization
This endpoint is defined as the proportion of patients with E2 \<30 pg/mL at 6 months, comparing patients who switch to GnRHa 1M versus those who continue GnRHa 3M therapy.
Time to adequate ovarian function suppression
Time frame · Assessed over a period of up to 12 months following randomization
This endpoint is defined as the time from the first occurrence of iOFS to the first measurement of E2 \<30 pg/mL.
Patient Age
Time frame · At randomization
Age of participants at the time of randomization, categorized by iOFS status (Persistent vs. Transient).
3-year invasive disease-free survival in patients who switch to GnRHa 1M versus those who continue GnRHa 3M therapy
Time frame · From the date of randomization until the date of locoregional recurrence, distant metastasis, second primary breast cancer, or death from any cause, up to 3 months
Invasive disease-free survival is defined as the time from randomization to the first occurrence of locoregional recurrence, distant metastasis, second primary breast cancer, or death from any cause.
3-year invasive disease-free survival in patients with persistent iOFS and those with transient iOFS
Time frame · From the date of randomization until the date of locoregional recurrence, distant metastasis, second primary breast cancer, or death from any cause, up to 3 months
Intraclass Correlation Coefficient (ICC) for the Consistency of the SEMS Method
Time frame · post SEMS assay
The consistency of the SEMS method will be assessed by calculating the Intraclass Correlation Coefficient (ICC) between GnRHa 1M and GnRHa 1M at the post-assay time point.
Adverse events
Time frame · From the date of treatment initiation until the date of disease progression, intolerable toxicities, death, withdrawal of consent, or completion of planned 3-year postoperative follow-up, whichever occurred first
Adverse events will be graded according to the NCI-CTCAE Version 5.0.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 45 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: Step 1：iOFS detection phase 1. Female, aged ≥18 and ≤45 years; 2. Histologically confirmed hormone receptor-positive (HR+) (estrogen receptor \[ER\] and/or progesterone receptor \[PR\] ≥1%) and human epidermal growth factor receptor 2-negative (HER2-) early invasive breast cancer (stage I-III according to the American Joint Committee on Cancer \[AJCC\], version 8)； 3. Completed curative surgery, with prior (neo)adjuvant chemotherapy and radiotherapy completed if applicable; 4. Currently receiving adjuvant therapy with a 3-month GnRH agonist (GnRHa) plus aromatase inhibitor (AI) or tamoxifen (TAM), with or without CDK4/6 inhibitors (excluding abemaciclib due to its potential interference with estradiol monitoring), for ≥1 dose, and presenting with estradiol (E2) ≥30 pg/mL within 28 days prior to enrollment (measured by CLIA). 5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; adequate bone marrow, hepatic, renal, and cardiac function. 6. Voluntarily sign a written informed consent form before the trial screening. Step 2：Randomized treatment phase 1. iOFS confirmed using the SEMS assay (E2 ≥30 pg/mL); 2. Ongoing adjuvant therapy with a 3-month GnRHa plus AI or TAM, with or without CDK4/6 inhibitors. 3. No evidence of disease progression. Exclusion Criteria: Step 1：iOFS detection phase 1. Bilateral breast cancer, inflammatory breast cancer, or distant metastasis; 2. Use of GnRHa for ovarian function preservation; 3. History of ovarian resection or ablation; planned pregnancy or breastfeeding; 4. Concomitant use of hormonal agents other than estrogen, progesterone, selective estrogen receptor modulators (SERM), or selective estrogen receptor degraders (SERD); 5. Severe uncontrolled comorbidities; 6. Other malignancies within the past 5 years (except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma); 7. Failure to comply with follow-up or psychiatric disorders. Step 2：Randomized treatment phase a)Prior conversion from a 3-month GnRHa to a 1-month GnRHa.
Study locations
0 registered sites.
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Goserelin.
NCT IDStudyPhase / statusEnrollmentUpdated
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI) · Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8
Phase 3
Active, not recruiting
608
2026-07
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Global Development, Inc. · Prostate Cancer
Phase 2
Recruiting
900
2026-07
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
National Cancer Institute (NCI) · Locally Advanced Salivary Gland Carcinoma · Metastatic Salivary Gland Carcinoma
Phase 2
Active, not recruiting
21
2026-07
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Systemic Lupus Erythematosus (Sle) · Primary Ovarian Insufficiency (Poi)
Not applicable
Recruiting
100
2026-07
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Dana-Farber Cancer Institute · Prostate Cancer · Prostatic Neoplasms
Phase 2
Recruiting
110
2026-07
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
LG Chem · Central Precocious Puberty
Phase 4
Recruiting
43
2026-07
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
ECOG-ACRIN Cancer Research Group · Prostate Carcinoma
Phase 3
Active, not recruiting
27
2026-07
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
National Cancer Institute (NCI) · Adult Ovarian Granulosa Cell Tumor
Phase 2
Active, not recruiting
17
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.